awmsg logo



metformin hydrochloride (Glucophage SR®)


Reference No. 3450

Publication date:
17/10/2017


Appraisal information

metformin hydrochloride (Glucophage SR®) 500 mg prolonged-release tablet
metformin hydrochloride (Glucophage SR®) 750 mg prolonged-release tablet
metformin hydrochloride (Glucophage SR®) 1000 mg prolonged-release tablet


Company: Merck Serono Ltd
BNF category: Endocrine system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 16/10/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, metformin hydrochloride (Glucophage SR®) cannot be endorsed for use within NHS Wales for the reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with IGT and/or IFG, and/or increased HbA1C who are: at high risk for developing overt type 2 diabetes mellitus and; still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months. Treatment with Glucophage SR® must be based on a risk score incorporating appropriate measures of glycaemic control and including evidence of high cardiovascular risk. Lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.
Statement of Advice (SOA)
Download